eCOA is no longer emerging. Sponsors have already committed to electronic patient-reported outcomes, and decentralized elements are now embedded in how modern trials are designed. The market continues to grow, adoption is widespread, and the technology has matured significantly.But maturity exposes a different kind of problem: not whether we can deploy eCOA, but whether we can operate it well after the initial release. The pressure point has shifted.
The protocol amendment burden and operational complexity
Multi-year clinical trials require ongoing platform upgrades and a majority of trials have protocol amendments. A report by Tufts University’s Center for the Study of Drug Development indicates more than 55% of all trials have at least one substantial amendment, each one setting off a chain reaction across live studies updates to instruments, translations, screenshots, testing, and redeployment. In global trials, where 20+ languages are routine even small changes become operationally complex. Without discipline, these changes introduce delays measured in weeks, not days with costs exceeding $500K for a Phase 3 trial for each amendment.
The issue isn’t whether an eCOA platform can launch a study. It’s whether teams can absorb protocol amendments, manage product releases, maintain databases, and support sites and patients globally without slowing the trial down.
A model designed for a different era
The industry’s current structure reflects where eCOA started. Technology providers built the platforms and, out of necessity, absorbed the surrounding study maintenance services such as device logistics, helpdesk, change requests, translations, and data management to make studies work.
That model was logical when builds were bespoke and tightly coupled to the system. But today, the environment looks different. Configuration is faster. Libraries are deeper. Workflows are more standardized. The effort required to stand up a study has meaningfully decreased.
What hasn’t decreased is the complexity of running one. Once a study is live, the real work of ongoing change management, database maintenance, release coordination, and global support begins. Every amendment, every language update, every protocol shift requires coordination across multiple stakeholders and systems.
This raises a more fundamental question for the industry:
Are we asking technology organizations to carry post go-live responsibilities they were never designed to own?
As eCOA continues to scale, a more deliberate separation is starting to make sense, one where platform innovation, study startup, and study maintenance are treated as distinct, equally critical capabilities.
Not as a handoff, but as a collaborative model built for scale.
Because the next phase of eCOA won’t be defined by who has the best tools. It will be defined by who can operate them with quality, speed, and without friction once the study is live.
The managed services model for eClinical technology
The managed services model is widely accepted across many industries. For eClinical technology, this outcome based model allows organizations to operationalize and scale eCOA delivery, supporting study startup, study maintenance, protocol amendments, translations, testing, UAT, product upgrades, and global study operations. This model helps reduce operational burden, reduce costs and deliver with quality, so eCOA providers can stay focused on innovation and site/patient experience.
For organizations feeling the strain between innovation and operations, a managed services model is becoming less optional and more inevitable.
